These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 18289006)

  • 41. Structure-activity relationship of group A streptococcus lipopeptide vaccine candidates in trimethyl chitosan-based self-adjuvanting delivery system.
    Nevagi RJ; Dai W; Khalil ZG; Hussein WM; Capon RJ; Skwarczynski M; Toth I
    Eur J Med Chem; 2019 Oct; 179():100-108. PubMed ID: 31247372
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Increased immunogenicity of HIV envelope subunit complexed with alpha2-macroglobulin when combined with monophosphoryl lipid A and GM-CSF.
    Liao HX; Cianciolo GJ; Staats HF; Scearce RM; Lapple DM; Stauffer SH; Thomasch JR; Pizzo SV; Montefiori DC; Hagen M; Eldridge J; Haynes BF
    Vaccine; 2002 May; 20(17-18):2396-403. PubMed ID: 12009296
    [TBL] [Abstract][Full Text] [Related]  

  • 43. P5 HER2/neu-derived peptide conjugated to liposomes containing MPL adjuvant as an effective prophylactic vaccine formulation for breast cancer.
    Shariat S; Badiee A; Jalali SA; Mansourian M; Yazdani M; Mortazavi SA; Jaafari MR
    Cancer Lett; 2014 Dec; 355(1):54-60. PubMed ID: 25224570
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Modulation of immune responses in Balb/c mice vaccinated with Brucella abortus Cu-Zn superoxide dismutase synthetic peptide vaccine.
    Tabatabai LB; Pugh GW
    Vaccine; 1994 Aug; 12(10):919-24. PubMed ID: 7526568
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bivalent mucosal peptide vaccines administered using the LCP carrier system stimulate protective immune responses against Streptococcus pyogenes infection.
    Schulze K; Ebensen T; Chandrudu S; Skwarczynski M; Toth I; Olive C; Guzman CA
    Nanomedicine; 2017 Nov; 13(8):2463-2474. PubMed ID: 28887213
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Innovative Vaccine Strategy: Self-Adjuvanting Conjugate Vaccines.
    Manabe Y; Fukase K
    Methods Mol Biol; 2023; 2613():55-72. PubMed ID: 36587070
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Fully synthetic self-adjuvanting thioether-conjugated glycopeptide-lipopeptide antitumor vaccines for the induction of complement-dependent cytotoxicity against tumor cells.
    Cai H; Sun ZY; Huang ZH; Shi L; Zhao YF; Kunz H; Li YM
    Chemistry; 2013 Feb; 19(6):1962-70. PubMed ID: 23280874
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Bioconjugation Approaches to Producing Subunit Vaccines Composed of Protein or Peptide Antigens and Covalently Attached Toll-Like Receptor Ligands.
    Xu Z; Moyle PM
    Bioconjug Chem; 2018 Mar; 29(3):572-586. PubMed ID: 28891637
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lipopeptide Nanoparticles: Development of Vaccines against Hookworm Parasite.
    Fuaad AA; Pearson MS; Pickering DA; Becker L; Zhao G; Loukas AC; Skwarczynski M; Toth I
    ChemMedChem; 2015 Oct; 10(10):1647-54. PubMed ID: 26269385
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Synthetic lipopeptide adjuvants and Toll-like receptor 2--structure-activity relationships.
    Spohn R; Buwitt-Beckmann U; Brock R; Jung G; Ulmer AJ; Wiesmüller KH
    Vaccine; 2004 Jun; 22(19):2494-9. PubMed ID: 15193414
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Vaccination with toxofilin DNA in combination with an alum-monophosphoryl lipid A mixed adjuvant induces significant protective immunity against Toxoplasma gondii.
    Song P; He S; Zhou A; Lv G; Guo J; Zhou J; Han Y; Zhou H; Hao Z; Cong H
    BMC Infect Dis; 2017 Jan; 17(1):19. PubMed ID: 28056837
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Lipopeptide vaccines--yesterday, today, and tomorrow.
    BenMohamed L; Wechsler SL; Nesburn AB
    Lancet Infect Dis; 2002 Jul; 2(7):425-31. PubMed ID: 12127354
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The hepatitis B virus-specific CTL responses induced in humans by lipopeptide vaccination are comparable to those elicited by acute viral infection.
    Livingston BD; Crimi C; Grey H; Ishioka G; Chisari FV; Fikes J; Grey H; Chesnut RW; Sette A
    J Immunol; 1997 Aug; 159(3):1383-92. PubMed ID: 9233635
    [TBL] [Abstract][Full Text] [Related]  

  • 54. OspA lipoprotein of Borrelia burgdorferi is a mucosal immunogen and adjuvant.
    Erdile LF; Guy B
    Vaccine; 1997 Jun; 15(9):988-96. PubMed ID: 9261945
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lipid core peptide/poly(lactic-co-glycolic acid) as a highly potent intranasal vaccine delivery system against Group A streptococcus.
    Marasini N; Khalil ZG; Giddam AK; Ghaffar KA; Hussein WM; Capon RJ; Batzloff MR; Good MF; Skwarczynski M; Toth I
    Int J Pharm; 2016 Nov; 513(1-2):410-420. PubMed ID: 27659862
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Intranasal vaccination with a lipopeptide containing a conformationally constrained conserved minimal peptide, a universal T cell epitope, and a self-adjuvanting lipid protects mice from group A streptococcus challenge and reduces throat colonization.
    Batzloff MR; Hartas J; Zeng W; Jackson DC; Good MF
    J Infect Dis; 2006 Aug; 194(3):325-30. PubMed ID: 16826480
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Recent advances in multivalent self adjuvanting glycolipopeptide vaccine strategies against breast cancer.
    Chentoufi AA; Nesburn AB; BenMohamed L
    Arch Immunol Ther Exp (Warsz); 2009; 57(6):409-23. PubMed ID: 19866342
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The influence of component structural arrangement on peptide vaccine immunogenicity.
    Alharbi N; Skwarczynski M; Toth I
    Biotechnol Adv; 2022 Nov; 60():108029. PubMed ID: 36028180
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A Th1-inducing adjuvant, MPL, enhances antibody profiles in experimental animals suggesting it has the potential to improve the efficacy of allergy vaccines.
    Wheeler AW; Marshall JS; Ulrich JT
    Int Arch Allergy Immunol; 2001 Oct; 126(2):135-9. PubMed ID: 11729351
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Synthesis of novel immunologically active tripalmitoyl-S-glycerylcysteinyl lipopeptides as useful intermediates for immunogen preparations.
    Metzger J; Wiesmüller KH; Schaude R; Bessler WG; Jung G
    Int J Pept Protein Res; 1991 Jan; 37(1):46-57. PubMed ID: 2045219
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.